The Future Hygiene and Health Company

Similar documents
Handelsbanken Nordic Large Cap Seminar. Magnus Groth, President and CEO

Interim Report Q1 2017

Year-end Report 2016

Year-end Report 2017

Interim Report Q3 2017

Interim Report Q Magnus Groth, President and CEO

SCA to Acquire BSN Medical, A Leading Medical Solutions Company. December 19, 2016

Year-end Report 2015

JANUARY 1 JUNE 30, 2017

Half-year Report Interim Report Q Magnus Groth, President and CEO

JANUARY 1 SEPTEMBER 30, 2018

Interim Report Q3 2018

JANUARY 1 MARCH 31, 2018

SCA Year-End Report January 31 December 2013

JANUARY 1 DECEMBER 31, 2017

Year-end Report Jan Johansson, President and CEO

SCA Interim Report Q2 2014

Annual Report SCA s vision is Dedicated to improving well-being through leading hygiene and health solutions

Information to SCA s shareholders

I n t e r i m R e p o r t Q

Financial Information

Financial Information

Annual and Sustainability Report 2017

AEGIS GROUP PLC 2008 ANNUAL RESULTS. 19 March 2009

Interim Report. 1 January 30 June 2012

Investor Presentation

Sanford C. Bernstein Strategic Decisions Conference

I n t e r i m R e p o r t Q

FY 2017 Results. March 6, 2018

Half-year 2012 Results. August 1, 2012

Investor Presentation

Press release Stockholm, March 6, 2017

ASSA ABLOY is the global leader in door opening solutions, dedicated to satisfying end-user needs for security, safety and convenience.

Sanford C. Bernstein Strategic Decisions Conference

Henkel AG & Co. KGaA. Klaus Keutmann Frankfurt,

Henrik Lange Executive Vice President and CFO

Henkel Roadshow Q November, 2014

I n t e r i m R e p o r t Q

Year-end Report JANUARY 31 DECEMBER 2009 (compared with corresponding period a year ago) CEO'S COMMENTS EARNINGS TREND

Investor Presentation

Interim Report. 1 January 31 March 2012

Interim Report Q1 2013

Full-year 2008 Results. February 19, 2009

Accelerating our IPT strategy

Interim report. 1 January 31 March I n t e r i m r e p o r t Q JANUARY 31 MARCH 2008 (compared with the same period previous year)

SCA Annual Report 2006

Hill-Rom Fourth Quarter 2016 Financial Results. November 3, 2016

2012 Interim Results - Presentation ZURICH, 23 AUGUST 2012

Henkel Shaping Henkel towards 2020 and beyond. Hans Van Bylen, Carsten Knobel German Investment Seminar 2017 January 2017

2007 Revenue and Results. 2007: strong increase in results Strengthened growth momentum. February 15 th, 2008

Finansforeningens Virksomhedsdag 2015 ISS. Heine Dalsgaard, CFO June 2015

Financial Value Creation. Stewart McCrone

William Blair Growth Stock Conference. June 13, 2012

Q in brief. Strong organic sales development. Electromechanical products up 25% Strong EBIT development. Strong cash flow

July 26, 2017 LafargeHolcim Ltd 2015

Nico Delvaux. President and CEO since 15 March. Belgian citizen, born in 1966

Valmet unique offering with process technology, automation and services. SEB Nordic Seminar January 8, 2019

ASSA ABLOY is the global leader in door opening solutions, dedicated to satisfying end-user needs for security, safety and convenience.

Mindray Medical International Limited. November 2011

Aegis Group plc Half Year Results. 27 August 2010

Huhtamaki Strong positions i for profitable growth. CEO Jukka Moisio Pohjola One-on-one Day March 9, 2011

Investor Presentation Q Results. 8 November 2018

ASSA ABLOY is the global leader in door opening solutions, dedicated to satisfying end-user needs for security, safety and convenience.

SCA Annual Report 2009

Investor Presentation Q Results. 8 November 2017

Investor Relations News November 16, Henkel presents growth strategy and financial targets for Outperform Globalize Simplify Inspire

Q in brief. Strong sales growth. One-off costs in China. Stable operating margin* Strong cash flow

Investor Presentation

Q in brief. Strong organic sales development. Electromechanical products up 30% Strong EBIT growth of 12%

Ontex H1 2018: Solid progress against 2018 priorities

Investor Presentation Q Results. 21 May 2015

B. Riley Investor Conference. May 23, 2018

1st Half 2010 Results. July 29, 2010

SECOND QUARTER REPORT 2009

highlights key figures dividend outlook organic revenue growth +5% earnings per share +16% continued investments in growth and innovations

Mindray Medical International Limited

P R E S S R E L E A S E

Philips Healthcare Financial Update. Ingo Bank, CFO Philips Healthcare

2017 Results and 2018 Outlook

UBS Healthcare Conference John J. Greisch, President and CEO. May 22, 2017

INVESTOR DAY INTRODUCTION 28 MAY 2014

Q Analyst & Investor Conference Call

Credit Suisse 6 th Annual Industrials Conference November 2018

Investor Deck December 2018

ELIOR GROUP FY RESULTS

J.P. Morgan Healthcare Conference

Half-year 2011 Results. July 29, 2011

I n t e r i m R e p o r t Q

Henkel Roadshow Presentation. As of November 2017

May 2017 Investor Meetings

Ontex H1 2017: Very Strong Broad-Based Revenue Growth

ROADSHOW POST-Q2 & H RESULTS. September 2016

BIC GROUP PRESS RELEASE CLICHY 01 AUGUST 2018 FIRST HALF 2018 RESULTS CHALLENGING TRADING ENVIRONMENT 2018 OUTLOOK UNCHANGED

Organic sales, which exclude exchange rate effects, acquisitions and divestments, increased by 2%

SCA Interim Report Q Moderator: Magnus Groth April 27, :00 a.m. CET

H.B. Fuller Company. J.P. Morgan Securities

2014 Results and 2015 Outlook

1st Quarter Revenue. April 22, 2010

ZEBRA TECHNOLOGIES SECOND-QUARTER 2016 RESULTS. August 9, 2016

Investors presentation. November 2011

Transcription:

The Future Hygiene and Health Company

This presentation may contain forward-looking statements. Such statements are based on our current expectations and are subject to certain risks and uncertainties that could negatively affect our business. Please read our most recent annual report for a better understanding of these risks and uncertainties. 2

Essity in Brief 101,238 SEK million in net sales 2016 Presence in approximately 11,992 SEK million in adjusted EBITA 1) 2016 150countries Note: 2016 figures exclude BSN medical, which will be consolidated as of April 3, 2017. 1) Excluding items affecting comparability. 2) As per 31 December 2016. Number of employees 2) 42,520 3

Essity s Business Leading global hygiene and health company #1 or #2 position in around 90 countries in at least one product segment Global market leader in incontinence products with TENA and in professional hygiene with Tork Strong brands and market positions Strong presence in emerging markets Acquisition of BSN medical, a leading medical solutions company Essity to split from SCA Group via a distribution and listing of the shares in Essity 4

Key Investment Highlights Operates in attractive markets supported by demographic trends Leading market positions and strong brands Strong presence in emerging markets Successful innovations strengthen product offerings BSN medical acquisition creates new growth platform Track record of profitable growth and high cash generation Focus on efficiency improvements and other measures to increase profitability 5

2016 Net Sales Essity (excluding BSN medical): SEK 101.2bn BSN medical: SEK 8.0bn 1) Personal Care 33% Baby Care 9% Feminine Care 7% Other 4% Incontinence Products 17% Consumer Tissue 41% Orthopedics 34% 37% Wound Care Professional Hygiene 26% 25% Compression Therapy 1) BSN medical will be integrated within Personal Care Business Area of Essity as of April 3, 2017. 6

2016 Net Sales by Geography Essity (excluding BSN medical): SEK 101.2bn Latin America Other 12% 1% BSN medical: SEK 8.0bn Latin America Middle East Africa 9% 4% Asia 15% 57% Europe Asia Pacific 15% 50% Europe North America 15% North America 22% 7

2016 Net Sales by Distribution Channel Essity (excluding BSN medical): SEK 101.2bn BSN medical: SEK 8.0bn Business to Business Healthcare Sector 26% 11% 63% Retail Trade Sanitary Shops Other 16% 23% 23% 38% Hospitals / Specialist Pharmacies 8

Global Market Positions Incontinence Products 1 Professional Hygiene 1 Consumer Tissue 2 Baby Care 4 Feminine Care 6 Medical Solutions 4 Source: The information has been compiled by Essity for presentation purposes based on statistics taken from external market sources including IRI, RISI, Price Hanna Consultants, SmartTRAK and INSIGHT Health. 9

Addressable Hygiene and Health Market By Region North America 33.2bn Europe 26.1bn Middle East & Africa 8.4bn Asia Pacific 32.9bn Latin America 11.2bn Bubble Size: Market size Global Market Size: EUR ~112bn 1) Source: The information has been compiled by Essity for presentation purposes based on statistics from external market sources including IRI, RISI, Price Hanna Consultants, SmartTRAK and INSIGHT Health. 1) Market values which refers to consumer tissue, professional hygiene, baby diapers, feminine care and incontinence products are based on 2016 data and market values which refers to medical solutions are based on 2015 data. 10

Addressable Hygiene and Health Market By Category Incontinence Products Medical Solutions 10% 8% Feminine Care 12% 37% Consumer Tissue Professional Hygiene 12% 21% Baby Diapers Global Market Size: EUR ~112bn 1) Source: The information has been compiled by Essity for presentation purposes based on statistics from external market sources including IRI, RISI, Price Hanna Consultants, SmartTRAK and INSIGHT Health. 1) Market values which refers to consumer tissue, professional hygiene, baby diapers, feminine care and incontinence products are based on 2016 data and market values which refers to medical solutions are based on 2015 data. 11

Favorable Market Trends Growing and Aging Global Population Increased Disposable Income and Higher Living Standards Urbanization Increased Prevalence of Chronic Conditions Increased Access to Healthcare Increased Awareness about Health & Hygiene 12

Usage of Hygiene Products High Potential in Markets with Low Penetration 500 400 300 200 100 0 Incontinence Products Baby Diapers Feminine Care Tissue 2 500 300 25 2 000 250 20 1 500 200 15 150 1 000 100 10 500 50 5 North America West Europé Eastern Europé Latinamerica Asia 0 North America West Europé Eastern Europé Latinamerica Asia 0 North America West Europé Eastern Europé Latinamerica Asia 0 North America West Europé Eastern Europé Latinamerica Asia Units/person with incontinence/year Units/child up to 2.5 years/year Units/woman 10-54 years/year Kg/capita/year North America Western Europe Eastern Europe Latin America Asia Source: The information has been compiled by Essity for presentation purposes based on statistics taken from external market sources including IRI, Price Hanna Consultants, National Macro Economics and RISI. 13

Strong Presence in Emerging Markets Emerging Markets accounts for 35% of Net Sales 2016 15% Asia Market Positions Incontinence Products Professional Hygiene Consumer Tissue Feminine Care Latin America #1 #3 #3 #1 12% Latin America Baby Diapers #6 65% 8% Rest EM Market Positions Incontinence Products Professional Hygiene Asia #3 #3 Consumer Tissue #1 In Emerging Markets, organic sales increased by 7% in 2016 Feminine Care Baby Diapers #12 #6 Source: The information has been compiled by Essity for presentation purposes based on statistics taken from external market sources including IRI, RISI and Price Hanna Consultants. 14

Strategic Framework VISION Dedicated to improving well-being through leading hygiene and health solutions MISSION To sustainably develop, produce, market and sell value-added products and services within hygiene and health Generate increased shareholder value through profitable growth Enable more people every day to enjoy a fuller life OBJECTIVES STRATEGIES Contribute to a sustainable and circular society Enable our employees to realize their full potential, as part of one winning team Win in chosen geographies and categories Focus on customers and consumers Innovate bigger brands Drive efficiency 15

Win in Chosen Geographies and Categories 16

BSN Medical A Value Creating Acquisition BSN medical develops, manufactures and sells products within wound care, compression therapy and orthopedics with well-known brands New growth platform and excellent strategic fit supporting Essity s vision Expected annual synergies of at least EUR 30m High cash conversion and an asset light business model Purchase price amounted to EUR 2,740m 1) Acquisition completed on April 3, 2017 To be included in Personal Care as Medical Solutions 2016 Facts Net sales SEK 8,038m Organic sales 2) +5.3% Adjusted EBITA 3) SEK 1,863m Number of employees ~6,000 Sales in number of countries ~140 1) Based on net debt as per December 31, 2016. Final takeover of net debt will be based on March 31, 2017. 2) Sales which excludes exchange rate effects, acquisitions and divestments. 3) Excluding items affecting comparability. 17

Category Strategies Consumer Tissue Professional Hygiene Incontinence Products Medical Solutions Baby Care Feminine Care Branded Value Growth Preferred Choice in Professional Hygiene Accelerate & Lead New Growth Platform Profitable Choices Invest into Growth 18

Innovate Bigger Brands Innovations Q1 2017 New Saba Good Night Re-launch of Libero in Russia TENA Flex with ConfioAir TENA Lady Discreet Familia ph Balanceado 19

Drive Efficiency 20

Tissue Roadmap Possibilities in creating value over the next 10 years Structural Potential Organic Potential Footprint Optimization Innovation & Quality Upgrades Technology Strategy Manufacturing Efficiency Sourcing & Energy Savings Capacity expansion in selected markets to capture growth Capex and restructuring costs will be required 21

Digital Strategy Digital Capabilities Digital Channels Digital Products 22

Essity Financial Profile (Excluding BSN Medical) Net Sales Adjusted EBITA 1) SEKbn 98.5 101.2 SEKbn 12.0 10.6 88.0 9.5 2014 2015 2016 Organic Sales +6% +3% Adjusted EBITA Margin 1) 2014 2015 2016 10.8% 10.8% 11.8% 1) Excludes items affecting comparability. 23

Essity Financial Targets and Policies Annual Organic Sales Growth 1) Adjusted Return on Capital Employed 2) Capital Structure Policy Dividend Policy >3% >15% To have an effective capital structure at the same time that the long-term access to debt financing is ensured Cash flow in relation to net debt shall take into account the target to maintain a solid investment grade rating Aims to provide long-term stable and rising dividends to its shareholders When cash flow from current operations exceeds what the company can invest in profitable expansion over the long-term and under the condition that the capital structure target is met the surplus shall be distributed to the shareholders 1) Excluding exchange rate effects, acquisitions and divestments. 2) Adjusted return on capital employed is accumulated return on capital employed and is calculated as 12-month rolling operating profit before amortization of acquisition-related intangible assets/ebita, excluding items affecting comparability, as a percentage of average capital employed for the five most recent quarters. 24

Examples of Profitability Enhancing Initiatives Value chain optimization Tissue roadmap Restructuring measures in France, Spain and the UK Investments in Mexico and the UK Cure or kill Discontinued hygiene business in India Exit Baby Care in Mexico Value creating acquisitions Wausau Paper Corp. BSN medical 25

Essity (Excluding BSN Medical) Financial Summary Q1 2017 vs Q1 2016 Net Sales Organic Sales 1) Adjusted EBITA 2) SEK 25,268m +4.2% +1.0% SEK 2,917m +6% Adjusted EBITA Margin 2) EPS Operating Cash Flow 11.5% +20bp SEK 2.08 SEK 3,086m +60% 1) Sales which excludes exchange rate effects, acquisitions and divestments 2) Excluding items affecting comparability 26

Summary and Key Takeaways Operates in attractive markets supported by demographic trends Leading market positions and strong brands Strong presence in emerging markets Successful innovations strengthen product offerings BSN medical acquisition creates new growth platform Track record of profitable growth and high cash generation Focus on efficiency improvements and other measures to increase profitability 27

Q&A 28